As PDUFA VIII negotiations begin and on-going debates on the best way to ensure patients can access medicines continue, biotech executives and investors are seeking clarity on how policy will impact their operational and investment decisions. Leaders from BIO and Washington policy and regulatory experts will share insights on what is known about developments at FDA, CMS, HHS and briefings with elected officials to create a policy and regulatory environment that leads to the shared goal of the best health outcomes for patients.